Cholinergic subcortical hyperintensities in Alzheimer's disease patients from the Sunnybrook dementia study: Relationships with cognitive dysfunction and hippocampal atrophy

Journal of Alzheimer's Disease

Volumn 43, Issue 3, 2015, Pages 785-796

  McNeely, Alicia A ^a,b,c   Ramirez, Joel ^a,b,c   Nestor, Sean M ^a,b,c,d   Zhao, Jiali ^a,b,c   Gao, Fuqiang ^a,b,c   Kiss, Alex ^a   Stuss, Donald T ^e,f   Black, Sandra E ^a,b,c,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c Canada   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Ontario Brain Institute   (Canada)

^f ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; cholinergic pathway; hippocampus; magnetic resonance imaging; memory; small vessel disease; subcortical hyperintensity

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROVASCULAR DISEASE; CHOLINERGIC NERVE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPAL ATROPHY; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SUNNYBROOK HIPPOCAMPAL VOLUMETRY TOOL; ATROPHY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATROPHY; CHOLINERGIC FIBERS; COGNITION; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84914709248     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140588     Document Type: Article

References (69)

1. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354, 919-920.
2. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
3. Gorelick PB (2004) Risk factors for vascular dementia and Alzheimer disease. Stroke 35, 2620-2622.
4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204.
5. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, Decarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG(2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37, 2220-2241.
6. Ramirez J, Gibson E, Quddus A, Lobaugh NJ, Feinstein A, Levine B, Scott CJ, Levy-Cooperman N, Gao FQ, Black SE (2011) Lesion Explorer: A comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage 54, 963-973.
7. Kertesz A, Black SE, Tokar G, Benke T, Carr T, Nicholson L (1988) Periventricular and subcortical hyperintensities on magnetic resonance imaging. 'Rims, caps, and unidentified bright objects'. Arch Neurol 45, 404-408.
8. Jang JW, Kim S, Na HY, Ahn S, Lee SJ, Kwak KH, Lee MA, Hsiung GY, Choi BS, Youn YC (2013) Effect of white matter hyperintensity on medial temporal lobe atrophy in Alzheimer's disease. Eur Neurol 69, 229-235.
9. Pantoni L (2010) Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9, 689-701.
10. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van BM, Norrving B, Gorelick PB, DichgansM(2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12, 822-838.
11. De Groot JC, De Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM (2001) Cerebral white matter lesions and subjective cognitive dysfunction: The Rotterdam Scan Study. Neurology 56, 1539-1545.
12. ChenYF,Wang H, ChuY, Huang YC, SuMY(2006) Regional quantification of white matter hyperintensity in normal aging, mild cognitive impairment, and Alzheimer's disease. Dement Geriatr Cogn Disord 22, 177-184.
13. Chang YT, Chang CC, Lin HS, Huang CW, Chang WN, Lui CC, Lee CC, Lin YT, Chen CH, Chen NC (2012) Montreal cognitive assessment in assessing clinical severity and white matter hyperintensity in Alzheimer's disease with normal control comparison. Acta Neurol Taiwan 21, 64-73.
14. Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE (2011) Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the Sunnybrook Dementia Study. J Alzheimers Dis 26 Suppl 3, 379-388.
15. Swartz RH, Stuss DT, Gao F, Black SE (2008) Independent cognitive effects of atrophy and diffuse subcortical and thalamico-cortical cerebrovascular disease in dementia. Stroke 39, 822-830.
16. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222.
17. Vermeer SE, Hollander M, van Dijk EJ, Hofman A,Koudstaal PJ, Breteler MM(2003) Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. Stroke 34, 1126-1129.
18. Nadkarni NK, McIlroy WE, Mawji E, Black SE (2009) Gait and subcortical hyperintensities in mild Alzheimer's disease and aging. Dement Geriatr Cogn Disord 28, 295-301.
19. Nadkarni NK, Studenski SA, Perera S, Rosano C, Aizenstein HJ, Brach JS,Van Swearingen JM (2013) White matter hyperintensities, exercise, and improvement in gait speed: Does type of gait rehabilitation matter J Am Geriatr Soc 61, 686-693.
20. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10, 122-126.
21. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66, 137-147.
22. Dumas JA, Newhouse PA (2011) The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol Biochem Behav 99, 254-261.
23. Bocti C, Swartz RH, Gao FQ, Sahlas DJ, Behl P, Black SE (2005) A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 36, 2126-2131.
24. Behl P, Bocti C, Swartz RH, Gao F, Sahlas DJ, Lanctot KL, Streiner DL, Black SE (2007) Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 64, 266-272.
25. Newman EL, Gupta K, Climer JR, Monaghan CK, Hasselmo ME (2012) Cholinergic modulation of cognitive processing: Insights drawn from computational models. Front Behav Neurosci 6, 24.
26. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM (1998) Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121, 2249-2257.
27. DeckerMW(1987) The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res 434, 423-438.
28. Mesulam MM, Geula C (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 275, 216-240.
29. Roman GC, Kalaria RN (2006) Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 27, 1769-1785.
30. den Heijer T, van der Lijn F, Koudstaal PJ, Hofman A, van der Lugt A, Krestin GP, Niessen WJ, Breteler MM (2010) A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 133, 1163-1172.
31. Schroeter ML, Stein T, Maslowski N, Neumann J (2009) Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 47, 1196-1206.
32. Teipel SJ, MeindlT, GrinbergL, Grothe M, Cantero JL, Reiser MF,Moller HJ, Heinsen H, Hampel H (2011) The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. Hum Brain Mapp 32, 1349-1362.
33. Swartz RH, Sahlas DJ, Black SE (2003) Strategic involvement of cholinergic pathways correlates with visuospatial and executive dysfunction: Does the location of white matter signal hyperintensities matter J Stroke Cerebrovasc Dis 12, 29-36.
34. Kim SH, Kang HS, Kim HJ, Moon Y, Ryu HJ, Kim MY, Han SH (2012) The effect of ischemic cholinergic damage on cognition in patients with subcortical vascular cognitive impairment. J Geriatr Psychiatry Neurol 25, 122-127.
35. Ishikawa H, Meguro K, Ishii H, Tanaka N, Yamaguchi S (2012) Silent infarction or white matter hyperintensity and impaired attention task scores in a nondemented population: The Osaki-Tajiri Project. J Stroke Cerebrovasc Dis 21, 275-282.
36. Chamelian L, Bocti C, Gao FQ, Black SE, Feinstein A (2005) Detecting cognitive dysfunction in multiple sclerosis with a magnetic resonance imaging rating scale: A pilot study. CNS Spectr 10, 394-401.
37. Kim HJ, Moon WJ, Han SH (2013) Differential cholinergic pathway involvement in Alzheimer's disease and subcortical ischemic vascular dementia. J Alzheimers Dis 35, 129-136.
38. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944.
39. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
40. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC.
41. Folstein MF, Folstein SE, McHugh PR (1975) "Mini Mental State" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
42. Mattis S (1988) Dementia Rating Scale (DRS), Psychological Assessment Resources, Odessa, FL.
43. Tippett WJ, Black SE (2008) Regional cerebral blood flow correlates of visuospatial tasks in Alzheimer's disease. J Int Neuropsychol Soc 14, 1034-1045.
44. Spreen O, Benton AL (1977) Neurosensory Center Comprehensive Examination for Aphasia, University of Victoria Neuropsychology Laboratory, Victoria.
45. Heaton RK (1981)Wisconsin Card Sorting Test manual. Psychological Assessment Resources, Odessa, Florida.
46. Benton AL, Hamsher K, Varney NR, Spuler S (1983) Contributions to Neuropsychological Assessment, Oxford University Press, New York.
47. Osterrieth PA (1944) Le test de copie d'une figure complexe. In Archives de psychologie, pp. 206-356
48. Delis DC, Kramer JH, Kaplan E, Ober BA (1987) California Verbal Learning Test: Adult Version. The Psychological Corporation, San Antonio, Texas.
49. Wechsler D (1987) Wechsler Memory Scale-Revised, The Psychological Corporation, New York.
50. Ramirez J, Scott CJ, Black SE (2013) A short-term scanrescan reliability test measuring brain tissue and subcortical hyperintensity volumetrics obtained using the lesion explorer structural MRI processing pipeline. Brain Topogr 26, 35-38.
51. Dade LA, Gao FQ, Kovacevic N, Roy P, Rockel C, O'Toole CM, Lobaugh NJ, Feinstein A, Levine B, Black SE (2004) Semiautomatic brain region extraction:Amethod of parcellating brain regions from structural magnetic resonance images. Neuroimage 22, 1492-1502.
52. Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with crosscorrelation: Evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12, 26-41.
53. Nestor SM, Gibson E, Gao FQ, Kiss A, Black SE (2013) A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease. Neuroimage 66C, 50-70.
54. Leung KK, Barnes J, Modat M, Ridgway GR, BartlettJW, Fox NC, Ourselin S (2011) Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 55, 1091-1108.
55. Pawlak M, Krejza J (2005) A new visual scale to assess white matter hyperintensities within cholinergic pathways. Stroke 36, 2064-2065.
56. Albert M, Massaro J, Decarli C, Beiser A, Seshadri S, Wolf PA, Au R (2010) Profiles by sex of brain MRI and cognitive function in the framingham offspring study. Alzheimer Dis Assoc Disord 24, 190-193.
57. Au R, Massaro JM, Wolf PA,Young ME, Beiser A, Seshadri S, D'Agostino RB, Decarli C(2006) Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 63, 246-250.
58. Massaro JM, D'Agostino RB Sr, Sullivan LM, Beiser A, Decarli C, Au R, Elias MF, Wolf PA (2004) Managing and analysing data from a large-scale study on Framingham Offspring relating brain structure to cognitive function. Stat Med 23, 351-367.
59. Mantyla R, Erkinjuntti T, Salonen O, Aronen HJ, Peltonen T, Pohjasvaara T, Standertskjold-Nordenstam CG (1997) Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort. Stroke 28, 1614-1623.
60. Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Malone IB, Schott JM, Rossor MN, Biessels GJ, Decarli C, Fox NC (2013) Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol Aging 34, 1996-2002.
61. Decarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, Beiser A, D'Agostino R, Wolf PA (2005) Measures of brain morphology and infarction in the framingham heart study: Establishing what is normal. Neurobiol Aging 26, 491-510.
62. Brisset M, Boutouyrie P, Pico F, Zhu Y, Zureik M, Schilling S, Dufouil C, Mazoyer B, Laurent S, Tzourio C, Debette S (2013) Large-vessel correlates of cerebral small-vessel disease. Neurology 80, 662-669.
63. Boone KB, Miller BL, Lesser IM, Mehringer CM, Hill-Gutierrez E, Goldberg MA, Berman NG (1992) Neuropsychological correlates of white-matter lesions in healthy elderly subjects. A threshold effect. Arch Neurol 49, 549-554.
64. Gao FQ, Pettersen JA, Bocti C, Nestor SM, Kiss A, Black SE (2013) Is encroachment of the carotid termination into the substantia innominata associated with its atrophy and cognition in Alzheimer's disease Neurobiol Aging 34, 1807-1814.
65. Brickman AM, Meier IB, Korgaonkar MS, Provenzano FA, GrieveSM, Siedlecki KL, Wasserman BT, Williams LM, Zimmerman ME (2012) Testing the white matter retrogenesis hypothesis of cognitive aging. Neurobiol Aging 33, 1699-1715.
66. Shi F, Liu B, Zhou Y, Yu C, Jiang T (2009) Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies. Hippocampus 19, 1055-1064.
67. Min D, Mao X, Wu K, Cao Y, Guo F, Zhu S, Xie N, Wang L, Chen T, Shaw C, Cai J (2012) Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci Lett 510, 29-33.
68. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A metaanalysis. CMAJ 169, 557-564.
69. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R (2003) Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34, 2323-2330.